Evidence map›Paper›PMID 39696038›Full record

ArticleBMC cancer2024

Identification of dimethyl 2,2'-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery.

Mubashir Aziz, Syeda Abida Ejaz, Pervaiz Ali Channar, Ali G Alkhathami, Tahir Qadri, Zahid Hussain, Mumtaz Hussaain, Rabail Ujan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mubashir AzizDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, 63100, Pakistan.
Syeda Abida EjazDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, 63100, Pakistan. abida.ejaz@iub.edu.pk.
Pervaiz Ali ChannarDepartment of Basic Science and Humanities, Faculty of Information Science Humanities, Dawood University of Engineering and Technology Karachi, Karachi, 74800, Pakistan.
Ali G AlkhathamiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O.Box 61413, Abha, 9088, Saudi Arabia.
Tahir QadriDepartment of Chemistry, University of Karachi, Karachi, 75270, Pakistan.
Zahid HussainDepartment of Chemistry, University of Karachi, Karachi, 75270, Pakistan.
Mumtaz HussaainDepartment of Chemistry, University of Karachi, Karachi, 75270, Pakistan.
Rabail UjanDr. M. A. Kazi Institute of Chemistry, University of Sindh, Jamshoro, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of the current study was to analyze and validate the existing gap in knowledge, by conducting a differential expression analysis and validation of NEK6, NEK7, and NEK9 in breast, cervical, and glioblastoma cancer and targeting these proteins through development of novel site specific inhibitor with favorable pharmacokinetic and safety profile, using open-source databases. The analysis revealed that the targeted kinases were overexpressed in all three types of cancer. Their expression was significantly linked to overall survival rates, which suggests that they play a major role in the development and progression of these cancers. After, having the prognostic importance of These findings provided a rationale for synthesizing novel compound i.e., dimethyl 2,2'-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4)), capable of effectively targeting these proteins using in-vitro cytotoxicity assays and comprehensive computational approaches. Then the inhibitory potential of TAJ4 was evaluated against cell lines of the respective cancers (HeLa cells, MCF-7 cells, and Vero cells). The growth inhibitory values (GI

Indexed as

Drug DiscoveryNIMA-Related KinasesAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationChlorocebus aethiopsFemaleHumansMolecular Docking SimulationProtein Kinase InhibitorsAntineoplastic AgentsNIMA-Related KinasesProtein Kinase InhibitorsBenzotriazole derivativeCytotoxicity assayExpression analysisIn-silico studiesNIMA related kinasesSingle-crystal analysis

Identifiers

PMID39696038
PMCPMC11658429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.